Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent
“We are pleased with the
In 2017, Minerva alleged that Hologic’s NovaSure® Advanced endometrial ablation system infringed a Minerva patent. In 2021, the district court issued a judgment in Hologic’s favor two weeks before trial, holding that Minerva’s patent is invalid.
Today’s affirmation by the
About NovaSure
The FDA approved the NovaSure endometrial ablation procedure in 2001 as safe and effective for women who suffer from abnormal uterine bleeding (AUB). The procedure provides a minimally invasive treatment option for women seeking an alternative to hormones or hysterectomy to treat their AUB, and since its introduction, more than 3 million women have been treated. The procedure has an efficacy rate of
About Hologic
Hologic, NovaSure, The Science of Sure and associated logos are trademarks and/or registered trademarks of
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.
1NovaSure Instructions for Use
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20230217005046/en/
Media Contact:
Vice President, Communications
(+1) 508.263.8654
jane.mazur@hologic.com
Investor Contact:
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
Source: